Published 26 Apr.2023 13:25(KST)
GemVax & Kael announced on the 26th that the global clinical trial of the Alzheimer's disease treatment GV1001 will be introduced as an outstanding achievement project of the Dementia Overcoming Research and Development Program.
On the 27th, the 'Dementia Overcoming Research and Development Program Phase 1 ('20~'22) Outstanding Achievement Sharing Meeting' will be held at the Oak Hall on the 4th floor of The Plaza Hotel in Seoul. The status of the Phase 2 clinical trials of GV1001, a new Alzheimer's disease treatment using peptides, in the United States and seven European countries will be presented.
The Dementia Overcoming Research and Development Program is a project jointly promoted by the Ministry of Science and ICT and the Ministry of Health and Welfare to support comprehensive research and development (R&D) covering dementia prevention, diagnosis, and treatment. The global clinical trial of GemVax's Alzheimer's disease treatment GV1001 was finally selected as a supported project by the program on December 31, 2020.
Among the 65 supported projects selected in Phase 1 of the Dementia Overcoming Research and Development Program, a total of seven projects, including GemVax, are scheduled to be introduced as outstanding achievements.
A GemVax representative stated, "During the program support period, we completed IND approvals in the United States and seven European countries," adding, "We achieved the milestone of starting clinical trials and enrolling subjects in the US and Europe." They further said, "This is a global clinical trial project under the Dementia Overcoming Research and Development Program and an advanced-stage project in the development of Alzheimer's disease treatments," and added, "We will devote ourselves to proving the therapeutic effects of GV1001 on Alzheimer's disease to contribute to reducing the nation's socioeconomic burden caused by dementia."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.